# Fycompa - (2,4,6,8,10,12 mg; Tablet, Oral)

| | | | |
|---|---|---|---|
| **Generic Name** | Perampanel | **Innovator** | EISAI INC |
| **Dosage** | 2,4,6,8,10,12 mg; Tablet, Oral | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | Less Than 5 |
| **Other ANDA developers** | More Than 5 | **Tentative Approvals** | Less Than 5 |
| **Final Approvals** | Less Than 5 | **Generic Launches** | Less Than 5 |
| **Indication** | FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

# Fycompa - (0.5 mg/mL ; Oral Suspension)

| | | | |
|---|---|---|---|
| **Generic Name** | Perampanel | **Innovator** | EISAI INC |
| **Dosage** | 0.5 mg/mL ; Oral Suspension | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | Less Than 5 |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | Less Than 5 | **Generic Launches** | Less Than 5 |
| **Indication** | FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated as adjunctive therapy for the treatment of: 1)Partial-Onset Seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older 2)Primary Generalized Tonic-Clonic Seizures in patients with epilepsy 12 years of age and older | | |
| **Complexities** | Yes | | |

## Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.